 |
Mang Yu, Ph.D., Chief Executive Officer
A winner of "Entrepreneur of 2008" award, Mang started his scientist-entrepreneur career 25 years ago, conducting biomedical research and teaching medical students as a faculty member at Fudan University in Shanghai. Under his direction, his present company, NexBio, has received numerous significant awards from the US government for drug development, including a $50M National Institutes of Health contract for the development of Fludase®, NexBio’s novel influenza medicine. In addition, NexBio has received the “Scientific American 50” award for this innovative drug. Prior to founding NexBio, Mang was co-founder and Executive Vice President of Perlan Therapeutics. Perlan’s lead product, ColdSol, a common cold medicine, won the CONNECT Award for Most Innovative New Product in 2002. Prior to Perlan, Mang was a scientific co-founder of Immusol (now ItherX Pharmaceuticals) where he served as Director of Target Discovery and Gene Therapy, working on HIV, HBV, and HCV. Among other outside business activities, Mang has served as a member of the Board of Director for Bridgetech Holding International, a publicly traded multinational healthcare company. He has also taught entrepreneurship classes for MBA students at SDSU. Mang has published his scientific work extensively, and holds numerous patents on antiviral products. In addition to working with the US government, he is experienced in venture capital financing and corporate partnership negotiations. Mang holds a Ph.D. in Biochemistry & Molecular Biology from Indiana University School of Medicine, and completed his post-doctoral training at UCSD.
|
 |
Fang Fang, M.D., Ph.D., President, Research and Development
A winner of the “Chief Scientist of 2008” award, Fang was named one of the People to Watch in the Life Sciences Industry. Prior to co-founding NexBio, she was the Scientific Founder of Perlan Therapeutics, where she was the inventor of Perlan’s lead drug, ColdSol, for which she won the CONNECT Most Innovative New Product award in 2002. Additionally, Fang was the 2003 recipient of the “Biopharma Award for Technology Innovation Leadership,” and was named one of the “10 San Diego Innovators of the Next Generation Technology Leadership” in the same year. At Perlan, Fang held three positions of increasing responsibility: Scientific and Medical Director, Vice President of Research and Development, and, Chief Scientific Officer. Fang has been awarded numerous significant grants and contracts from the National Institutes of Health and the National Institutes of Allergy and Infectious Diseases. Fang holds an MD degree from Peking Union Medical College, and completed her residency at Massachusetts General Hospital, a Harvard teaching hospital. Fang holds a Ph.D. degree in Cell Biology from UCSD, completed her post-doctoral training at the Burnham Institute and served as a physician scientist at the Salk Institute.
|
 |
Ronald B. Moss, M.D., Executive VP, Clinical Development & Medical Affairs
Ron brings to NexBio 22 years of research and clinical experience, including 15 years of pharmaceutical drug development experience ranging from Phase 1 to NDA, and extensive expertise in clinical, regulatory and quality affairs. He previously worked at several biopharmaceutical companies in various capacities including Rhone Poulenc Rorer (now Aventis), Immune Response Corporation, Telos and Merck, where he was Senior Director of Worldwide Regulatory Affairs for Vaccines/Biologics in the Merck Research Laboratories division. Most recently, he was Vice President of Clinical Development at Vical, Inc., a publicly-traded company, where he guided the clinical development of various biological products for emerging infectious diseases, including U.S. Government-funded development of a pre-pandemic influenza vaccine. Ron earned his M.D. degree at the Chicago Medical School, having graduated Phi Beta Kappa with a bachelor's degree from the State University of New York at Stony Brook (SUNY). He completed his residency in Pediatrics at SUNY, followed by a fellowship at the National Institute of Allergy and Infectious Disease, where he was Clinical Associate in Allergy and Clinical Immunology. Ron is Board-certified in both Pediatrics and Allergy & Immunology.
|
 |
Chuck Olson, DSc; Sr. VP, Product Development and Operations
Chuck is responsible for the company’s drug substance and drug product process development, analytical and bioanalytical development, manufacturing, quality and facilities operations. He spent a significant early portion of his 27 year career at Genentech and Bayer respectively, focusing on process development and protein characterization. As a result, Chuck is a drug developer with unique scientific understanding of, and broad operational experience with, recombinant protein based products. He possesses the leadership skills necessary to bring promising new products through development to market. His combined experiences at both startup and established companies has afforded him with valuable skills to resolve critical technical issues decisively and to overcome systems related obstacles, as well as to actively manage crucial risk/benefit situations. Before joining NexBio, Chuck was Vice President at Cell Genesys for its Hayward Operations, where as the site general manager, he was responsible for a ~100,000 sq ft biotech facility with over 120 employees representing all facets of cGMP operations. Previously, Chuck was Sr. Director, Manufacturing, Facilities and Process Development at BioMarin Pharmaceuticals. He has also held the position of Director, Manufacturing Sciences at Onyx Pharmaceuticals. Chuck holds a masters degree in chemistry and a doctoral degree in biochemistry.
|
 |
David Wurtman, M.D., M.B.A., VP, Corporate Development
David is in charge of business development, public relations, intellectual property, and general strategic planning and execution. A board-certified internist, David received his M.D. degree from the Harvard University School of Medicine and practiced medicine on the staff of a Harvard teaching hospital. Subsequently, David worked at S.G. Cowen in the pharmaceutical analyst group, and then obtained his MBA from the Sloan School of Management at MIT. He began his corporate development career at Genzyme, after which he moved to Eos Biotechnology, where he headed up business development. He participated in the sale of Eos to PDL BioPharma, which he then joined as Sr. Director of Corporate Development after the closing. He later formed and headed the Albion Consulting Group, offering corporate and business development, new product and portfolio planning, and market research advice to early-stage biotechnology companies. He has completed numerous licensing deals with corporate partners such as Roche, Otsuka, PDL BioPharma, Biogen, Aventis Pasteur, Seattle Genetics, ICOS, Medarex, Kai, Xenerex, R&D Systems and pH Advantage.
|
|
|
Dongmei Wang, C.P.A., Assistant VP, Finance and Administration
Dongmei is in charge of multiple business functions at NexBio, including finance, accounting, human resources, and administration. Prior to joining NexBio, Dongmei held management positions of increasing responsibility at several companies, including Progeny Systems and AutoGenomics. Most recently, Dongmei was Director of Finance and Controller for AutoGenomics, Inc. Dongmei has also held the titles of Auditor, Senior Accountant /Analyst, Accounting Manager, and Controller. In addition to her extensive experience in finance, Dongmei has hands-on experience in human resources and business administration. Dongmei is a licensed Certified Public Accountant (CPA), and holds a Master’s degree of International Management from the University of St. Thomas and a BS degree in Accounting from University of Minnesota.
|
 |
Cal Bowman, J.D., RAC, Executive Consultant, Quality Assurance and Regulatory Affairs
Cal has over 20 years of senior management experience in Quality Assurance and Regulatory Affairs at the Vice President level at small, medium, and large pharmaceutical companies. Before joining NexBio, Cal was Vice President of Regulatory Affairs at Eisai, one of the top 25 pharmaceutical companies in the world. He has been responsible for successfully obtaining over 75 NDAs, ANDAs, BLAs, and PMAs, in the US and over 50 European and Asian approvals. Cal has also served as a board member of the Regulatory Affairs Professional Society and acted as chairman of the regulatory arms of 3 major trade organizations. In addition to significant experience in Quality Assurance and Regulatory Affairs, Cal has served in senior management roles in Clinical and Information Technology departments. Cal obtained his BA degree from Brigham Young University (Pre-Med) and his J.D. degree from Western State University, College of Law. Cal is Regulatory Affairs Certified by the Regulatory Affairs Professional Society, and is a Certified Quality Manager and Auditor by the American Society of Quality.
|
|
